Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
03/22/2018
Trade Name:
Symfi
Generic Name or Proper Name (*):
efavirenz, lamivudine and tenofovir disoproxil fumarate
Indications Studied:
Treatment of HIV-1 infection in adult and pediatric patients weighing at least 40 kg
Label Changes Summary:
*Safety and effectiveness of Symfi as a fixed-dose tablet in pediatric patients infected with HIV-1 and weighing at least 40 kg have been established based on clinical studies using the individual components (efavirenz, lamivudine, and tenofovir disoproxil fumarate). *New drug.
PREA(P):
P
Sponsor:
Mylan
NNPS:
FALSE
Therapeutic Category:
Antiviral
-
-